Suman Kambhampati

Suman Kambhampati

Hematology
4000 Cambridge Street
Kansas City, KS 66160

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications

Converging Pathways in Cancer Biology: How Do the Microbiome, Angiogenesis, Senescence, Fibroblast Plasticity, and Immunotherapy Intertwine?

Converging Pathways in Cancer Biology: How Do the Microbiome, Angiogenesis, Senescence, Fibroblast Plasticity, and Immunotherapy Intertwine?

Journal: Cancers
Published: February 15, 2026

Targeted Nanoencapsulation of Tunicamycin Reduces Toxicity While Improving its Therapeutic Effectiveness in Pancreatic Cancer Cells.

Targeted Nanoencapsulation of Tunicamycin Reduces Toxicity While Improving its Therapeutic Effectiveness in Pancreatic Cancer Cells.

Journal: Research square
Published: June 05, 2025

Targeted nanoencapsulation of tunicamycin reduces toxicity while improving its therapeutic effectiveness in pancreatic cancer cells.

Targeted nanoencapsulation of tunicamycin reduces toxicity while improving its therapeutic effectiveness in pancreatic cancer cells.

Journal: Molecular therapy. Oncology
Published: March 13, 2025

Dofetilide unmasks long QT in a patient presenting with atrial fibrillation-induced cardiomyopathy.

Dofetilide unmasks long QT in a patient presenting with atrial fibrillation-induced cardiomyopathy.

Journal: HeartRhythm case reports
Published: December 12, 2024

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.

Journal: Blood
Published: June 28, 2024

In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.

In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.

Journal: Future oncology (London, England)
Published: October 09, 2023

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 13, 2023

Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting.

Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting.

Journal: Clinical hematology international
Published: May 24, 2023

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.

Journal: Blood cancer journal
Published: May 16, 2023

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 08, 2023

Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.

Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 10, 2022

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.

Journal: Blood advances
Published: February 15, 2022
Showing 1-12 of 52

Last Updated: 09/26/2026